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Hydroxyurea Use and Measurement
People with sickle cell disease (SCD) in the United States 
are living longer, healthier lives because of advances in 
treatment and prevention of complications. One of the 
goals of the PHRESH project was to find out how well 
those advances are reaching individuals in Georgia. 
Another goal was to help the Centers for Disease Control 
and Prevention (CDC) develop practical ways to collect 
data on SCD-related objectives for Healthy People 2020 
(HP2020). 
Hydroxyurea drug therapy has been shown to reduce 
complications associated with SCD in adults and children, 
improve quality of life, and increase longevity. Increased 
use of this treatment fulfills HP2020 Blood Disorders and 
Blood Safety objectives 5: “Increase the proportion of persons with hemoglobinopathies who receive disease modifying 
therapies.” We used RuSH data to determine the proportion of individuals who met diagnostic and clinical criteria for 
hydroxyurea treatment and filled a prescription for the medication during the surveillance period of 2004-2008. This brief 
presents our findings and discusses options for ongoing tracking of this HP2020 objective.
Indications for Use
Hydroxyurea—developed as a cancer treatment—has been shown to reduce episodes of pain and acute chest syndrome, 
to reduce anemia and the need for transfusions, and to improve the quality of life in children and adults with HbSS and 
HbSβ0 thalassemia. There is evidence from around the world that individuals with these types of SCD who are taking 
hydroxyurea are living longer than those who are not. Currently, there is little data showing benefit to persons with HbSC 
or HbSβ+ thalassemia. Our surveillance data are unique in allowing us to assess hydroxyurea use in individuals who have 
the two specific types of SCD with evidence of benefit.   
In addition to the specific types of SCD for which the drug is indicated, clinical guidelines in place during the five-year 
surveillance period recommended hydroxyurea treatment for patients experiencing the most acute complications – 
specifically, those who had one episode of acute chest syndrome or three episodes of SCD crisis within a year. In our 
surveillance dataset, we identified the individuals who met at least one of these clinical indications for hydroxyurea and, of 
those, the proportion who filled a prescription for it. We analyzed the data separately for children (0-19 years of age) and 
adults (20 years of age and older) because the evidence base for hydroxyurea use in children was less firmly established in 
2004-2008 than it is today.
This project is supported by Cooperative Agreement 5U50DD001010 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility 
of the authors and do not necessarily represent the official views of CDC. For more information and additional resources, please visit www.ghpc.gsu.edu/phresh.
Currently, few data sources other than clinical center-based registries allow identification of individuals with specific types of 
SCD. However, claims-based health insurance datasets can be used to identify the population of all individuals with SCD who 
meet clinical criteria and the proportion for whom a hydroxyurea prescription is filled. Thus, claims data represent a feasible 
and satisfactory source for baseline and ongoing measurement of hydroxyurea use to track adherence to guidelines and 
achievement of HP2020 objectives.
  
A 2014 NIH Expert Panel Report includes evidence-based guidelines that recommended increased adoption of hydroxyurea 
in the care of individuals with SCD. These guidelines and our booklet, Sickle Cell Disease Treatment: Important Information 
for Patients and Health Care Providers, further discuss the evidence, risks, and benefits of hydroxyurea. 
Update: See the 11/19/2014 media advisory from NIH on new, positive findings regarding hydroxyurea use with TCD to 
reduce stroke risk.
Results
RuSH surveillance identified 16,504 individuals with confirmed, probable, or possible SCD who lived in Georgia between 
2004 and 2008. We have public health insurance claims data matched to roughly three-fourths of these (12,340), which we 
used to determine who met the clinical criteria for hydroxyurea use described above. RuSH data include 4,288 cases for which 
the specific type of SCD is confirmed; and 2,840 of these have HbSS or HbSβ0 thalassemia. We have public health insurance 
claims data matched to approximately three-quarters of cases (2,131) in this group as well. Table 1 shows the proportion of 
individuals meeting treatment criteria in both groups that filled at least one prescription for hydroxyurea.
Conclusion
Among all possible cases of SCD, 30% of individuals (29% of children, 32% of adults) who met the clinical criteria for 
hydroxyurea treatment filled a prescription. Among confirmed cases with the SCD types for which hydroxyurea has 
demonstrated benefit, the portion meeting clinical criteria who received hydroxyurea increased to 38% (36% of children, 42% 
of adults). These results indicate that hydroxyurea was underutilized in Georgia in 2004-2008.
Table 1. Hydroxyurea Treatment in Children and Adults Who Met Clinical Criteria, 2004-20081
Population and age group2
Met clinical criteria3 Filled a prescription for hydroxyurea
Number Number Percent
Confirmed, probable, or 
possible SCD 2,862 858 30%
0-19 years of age 1,581 453 29%
20 years of age or older 1,281 405 32%
Confirmed HbSS or HbSβ0 
thalassemia 1,429 537 38%
0-19 years of age 952 339 36%
20 years of age or older 477 198 42%
1Data: Georgia RuSH cases matched to Medicaid, CHIP, or State Health Benefit Plan claims
2Age as of the date when clinical criteria were met
3Clinical criteria: At least 1 acute chest syndrome or 3 SCD crises within the past 365 days
